OpenLobby.EU
Explore

Daikin Chemical Europe GmbH

Supply of high-performance chemicals which are used in various industries with attention to the environmental footprint

Lobbying Activity

Response to Persistent organic pollutants: long-chain perfluorocarboxylic acids, their salts and related compounds.

16 Dec 2025

We appreciate the opportunity to provide feedback on the proposed amendment to Regulation (EU) 2019/1021 of the European Parliament and of the Council concerning long-chain perfluorocarboxylic acids (LC PFCAs), their salts, and related substances. . Our feedback focuses on the proposed derogation for fluoroplastics and fluoroelastomers containing perfluoroalkoxy groups (paragraph 4), which explicitly excludes articles from its scope, and the proposed derogation for PTFE micro powders (paragraph 5). Please find our comments in the attached file. Thank you for your consideration.
Read full response

Meeting with Paul Speight (Head of Unit Environment)

7 Oct 2025 · PFAS restriction and listing of long-chain perfluorocarboxylic acids in the POPs Regulation

Meeting with Vita Jukne (Cabinet of Commissioner Jessika Roswall)

14 Jul 2025 · Chemical action plan and Chemical Industry Package.

Meeting with Dennis Radtke (Member of the European Parliament)

3 Jun 2025 · Reach Regulation

Meeting with Hildegard Bentele (Member of the European Parliament) and Kreab Worldwide

26 Mar 2025 · Water Resilience

Meeting with Patrizia Toia (Member of the European Parliament, Shadow rapporteur)

22 Mar 2023 · F-Gas

Meeting with César Luena (Member of the European Parliament)

14 Feb 2023 · MEP Luena's Team on Fluorinated greenhouse gases

Meeting with Christine Schneider (Member of the European Parliament)

18 Jan 2023 · F-Gas

Meeting with Stelios Kympouropoulos (Member of the European Parliament, Shadow rapporteur) and DAIKIN Europe NV

19 Jul 2022 · pMDIs, phase out of f-gases

Response to Review of EU rules on fluorinated greenhouse gases

28 Jun 2022

This is a statement by Daikin Chemical Europe GmbH and focuses on the topic of MDIs only. Daikin Chemical Europe GmbH (Dusseldorf, Germany) belongs to the Daikin Group together with Daikin Europe N.V.. While Daikin Europe N.V. produces equipment such as air-conditioning, heat pumps and refrigeration, Daikin Chemical Europe is one of the largest suppliers of high performance fluorochemical products in Europe. On 5 April 2022, the Commission made a legislative proposal to update the 2014 F-Gas Regulation - the key piece of legislation reducing the consumption of HFCs (hydrofluorocarbons) through a F-gas quota phase-down and stimulating innovation by encouraging the use of green technologies based on less climate-harmful alternatives. The new F-gas proposal forms part of the Emissions and Pollutants Package supporting the EU's ambition to achieve a 55% reduction of GHG emissions by 2030, and climate neutrality by 2050. HFCs are F-gases used in various sectors and applications, such as refrigerants in refrigeration, air-conditioning & heat pump equipment and also in medical devices such as propellants in Metered Dose Inhalers (MDIs). MDIs are widely used in drug-combination products which play an essential role in medical care to vulnerable patients such as asthma and COPD (Chronic Obstructive Pulmonary Disorder) sufferers. MDIs are particularly appreciated by the medical community as they are easy to use by patients – which is why they are often the delivery system of choice for the young and the elderly. Daikin Chemical Europe is one of the largest suppliers of high performance fluorochemical products in Europe and the only global producer of medical propellant HFC-227ea pharma used in MDIs. The new proposal does not foresee a separation between the quota allocated for HFCs used in MDIs and the quota allocated for HFCs used in RACHP (refrigeration, air conditioning and heat pumps) so that a competition between the two sectors may be the result. The use of pharmaceutical grade F-gases in MDIs remains necessary for the health and safety of patients suffering from and being treated for lung diseases such as asthma & COPD. Whilst the 2014 F-gas Regulation exempted HFCs used in MDIs from the F-gas quota phase-down, the Commission has now proposed to lift this exemption. The Commission argues that climate-friendly alternatives (with lower Global Warming Potential – GWP) are available which can replace HFCs currently used in MDIs (HFC-134a which accounts for around 92% of the propellant market and HFC-227ea making up the rest). The Commission believes this change of propellant will not require any adaptation of the MDI devices used by patients and states that the approval process for new propellants by the European Medical Authority is under way. Daikin Chemicals is supportive of the EU’s ambition to make Europe carbon neutral by 2050. However: - At present no market-ready alternative exists for HFC-227ea pharma; - We strongly support that no final decision on the introduction of a quota system for HFCs used in MDIs is taken whilst the commercial availability of a suitable alternative is unknown. When an alternative is available, a reformulation and clinical trial of the medicine with the new propellant would need to be undertaken. Since this takes time, we support a postponement of the removal of the exemption for MDIs to 2030; - Even after this, imposing a rapid phase-down of current propellants in MDIs must be proportionate and to the needs of the patient receiving healthcare; - The quota allocated for F-gases used in MDIs and the quota allocated for F-gases used in RACHP should be kept separate from each other in order to avoid the competition of the two sectors; - Changes to medical treatment should be driven by clinical considerations and patient preference. It is essential that patients with serious and complex respiratory diseases are able to benefit from the most effective medicines tailored to their individual need.
Read full response

Response to Persistent organic pollutants - perfluoroctanoic acid

13 Jun 2022

Please see file attached.
Read full response